<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01359410</url>
  </required_header>
  <id_info>
    <org_study_id>06-1192</org_study_id>
    <nct_id>NCT01359410</nct_id>
  </id_info>
  <brief_title>Reinforced Staple Line on Leak Rate in Distal Pancreatectomy</brief_title>
  <official_title>Effect of a Reinforced Staple Line on Leak Rate in Distal Pancreatectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose a randomized, controlled trial of stapled pancreatic transection
      versus mesh reinforced stapled pancreatic transection. For the duration of the study period,
      participating surgeons will utilize a standardized staple technique. Either a reabsorbable
      polytrimethylene carbonate mesh (SEAMGUARD®) or reabsorbable strips of bovine pericardium
      (PERI-STRIPS DRY®) will be used to reinforce the stapled pancreatic transection line in the
      test group. In order to have a uniform test method, the investigators will utilize a
      laparoscopic stapling device for both open and laparoscopic procedures and a uniform staple
      size (4.8mm).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic leak remains a significant cause of morbidity and extra cost following distal
      pancreatectomy. Historically, previous attempts to reduce the leak rate have met with limited
      success. To examine this problem the investigators propose a randomized, controlled trial of
      stapled pancreatic transection versus mesh reinforced stapled pancreatic transection. For the
      duration of the study period, participating surgeons will utilize a standardized staple
      technique. Either a reabsorbable polytrimethylene carbonate mesh (SEAMGUARD®) or reabsorbable
      strips of bovine pericardium (PERI-STRIPS DRY®) will be used to reinforce the stapled
      pancreatic transection line in the test group. In order to have a uniform test method, the
      investigators will utilize a laparoscopic stapling device for both open and laparoscopic
      procedures and a uniform staple size (4.8mm). A drain will be placed in the left upper
      quadrant at the time of resection. Drainage of the pancreatic resection bed is widely
      accepted and remains our current standard of care.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The 3rd interim analysis found superiority in the mesh reinforcement arm
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Participant's were blinded to the results of the randomization for 6 weeks.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Clinically Significant Postoperative Pancreatic Leak at Any Time as Defined by the ISGPF Pancreatic Leak Grading System</measure>
    <time_frame>100 days or removal of drain</time_frame>
    <description>Identified as being a grade B or grade C fistula or any fistula that altered the patients' management in any way
Determination of severity of pancreatic fistula was done using the ISGPF(International Study Group Pancreatic Fistula) leak/fistula/pancreatic occlusion failure
Grade B: &gt;3x normal serum amylase, often well clinical condition, yes/no specific treatment, negative/positive ultrasound/CT, usually persistent drainage (&gt;3 weeks), yes/no signs of infection, yes/no readmission, no sepsis, no reoperation, no death related to fistula
Grade C: &gt;3x normal serum amylase, ill appearing/bad, requires specific treatment, positive ultrasound/CT, persistent drainage (&gt;3 weeks), signs of infection, yes/no readmission, sepsis, reoperation, and death related to fistula</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Any Fistula as Defined by the ISGPF Pancreatic Leak Grading System</measure>
    <time_frame>100 days or removal of drain</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Drain Removal</measure>
    <time_frame>100 days or removal of drain</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Non-pancreatic Adverse Events</measure>
    <time_frame>100 days or removal of drain</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Stapled transection with mesh reinforcement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stapled transection without mesh reinforcement</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mesh reinforced staple line (SEAMGUARD)</intervention_name>
    <description>Reinforce the pancreatic transaction with SEAMGUARD®</description>
    <arm_group_label>Stapled transection with mesh reinforcement</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stapled without mesh reinforcement (PER-STRIPS DRY)</intervention_name>
    <description>Stapled without mesh reinforcement (PERI-STRIPS DRY®)</description>
    <arm_group_label>Stapled transection with mesh reinforcement</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be 18 years or older and able to give consent. Any patient
             undergoing a distal pancreatectomy, laparoscopic or open, will be eligible for
             randomization.

          -  No exclusion is provided for primary diagnosis. In the event of a patient undergoing a
             planned resection of another organ or organs with only a possibility of a distal
             pancreatic resection (i.e. colectomy, hepatectomy, gastrectomy, nephrectomy), the
             patient will still be eligible for inclusion in the study. We expect that some
             patients will be randomized but not resected (ie metastasis identified). A few
             patients may not be stapled using the study device for technical reasons (ie the
             stapler does not fit). The data will be analyzed in an intent-to-treatment approach.

        Exclusion Criteria: None specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Hawkins, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Hawkins WG. To mesh or not to mesh, that is the question: comment on &quot;Use of Seamguard to prevent pancreatic leak following distal pancreatectomy&quot;. Arch Surg. 2009 Oct;144(10):899.</citation>
    <PMID>19852096</PMID>
  </reference>
  <reference>
    <citation>Johnston FM, Cavataio A, Strasberg SM, Hamilton NA, Simon PO Jr, Trinkaus K, Doyle MB, Mathews BD, Porembka MR, Linehan DC, Hawkins WG. The effect of mesh reinforcement of a stapled transection line on the rate of pancreatic occlusion failure after distal pancreatectomy: review of a single institution's experience. HPB (Oxford). 2009 Feb;11(1):25-31. doi: 10.1111/j.1477-2574.2008.00001.x.</citation>
    <PMID>19590620</PMID>
  </reference>
  <reference>
    <citation>Thaker RI, Matthews BD, Linehan DC, Strasberg SM, Eagon JC, Hawkins WG. Absorbable mesh reinforcement of a stapled pancreatic transection line reduces the leak rate with distal pancreatectomy. J Gastrointest Surg. 2007 Jan;11(1):59-65.</citation>
    <PMID>17390188</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2011</study_first_submitted>
  <study_first_submitted_qc>May 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <results_first_submitted>March 29, 2017</results_first_submitted>
  <results_first_submitted_qc>March 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2017</results_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pancreas adenocarcinoma</keyword>
  <keyword>Precancerous lesions of the pancreas (mucinous cystic neoplasms, IPMN)</keyword>
  <keyword>Pancreas neuroendocrine cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study opened to participant enrollment on 06/28/2007 and closed to participant enrollment on 10/28/2011.</recruitment_details>
      <pre_assignment_details>112 participants were enrolled to the study but 12 participants (1 participant declined to be in the study and 11 participants were found to be ineligible) were excluded from the study before randomization to the arms.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stapled Transection With Mesh Reinforcement</title>
          <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
        </group>
        <group group_id="P2">
          <title>Stapled Transection Without Mesh Reinforcement</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="46"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Stapled Transection With Mesh Reinforcement</title>
          <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
        </group>
        <group group_id="B2">
          <title>Stapled Transection Without Mesh Reinforcement</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="46"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="15.6"/>
                    <measurement group_id="B2" value="58.6" spread="13.4"/>
                    <measurement group_id="B3" value="58.0" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Indication for operation</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Adenocarcinoma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neuroendocrine tumor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Metastatic tumor to pancreas</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Benign pancreatic tumor</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Chronic pancreatitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Normal pancreas</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Nonsmoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Smoker</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinically Significant Postoperative Pancreatic Leak at Any Time as Defined by the ISGPF Pancreatic Leak Grading System</title>
        <description>Identified as being a grade B or grade C fistula or any fistula that altered the patients' management in any way
Determination of severity of pancreatic fistula was done using the ISGPF(International Study Group Pancreatic Fistula) leak/fistula/pancreatic occlusion failure
Grade B: &gt;3x normal serum amylase, often well clinical condition, yes/no specific treatment, negative/positive ultrasound/CT, usually persistent drainage (&gt;3 weeks), yes/no signs of infection, yes/no readmission, no sepsis, no reoperation, no death related to fistula
Grade C: &gt;3x normal serum amylase, ill appearing/bad, requires specific treatment, positive ultrasound/CT, persistent drainage (&gt;3 weeks), signs of infection, yes/no readmission, sepsis, reoperation, and death related to fistula</description>
        <time_frame>100 days or removal of drain</time_frame>
        <population>(1) participant in the mesh reinforcement arm was not evaluable due to death and (1) participant in the non-mesh reinforcement arm was not evaluable due to death.</population>
        <group_list>
          <group group_id="O1">
            <title>Stapled Transection With Mesh Reinforcement</title>
            <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
          </group>
          <group group_id="O2">
            <title>Stapled Transection Without Mesh Reinforcement</title>
          </group>
        </group_list>
        <measure>
          <title>Clinically Significant Postoperative Pancreatic Leak at Any Time as Defined by the ISGPF Pancreatic Leak Grading System</title>
          <description>Identified as being a grade B or grade C fistula or any fistula that altered the patients' management in any way
Determination of severity of pancreatic fistula was done using the ISGPF(International Study Group Pancreatic Fistula) leak/fistula/pancreatic occlusion failure
Grade B: &gt;3x normal serum amylase, often well clinical condition, yes/no specific treatment, negative/positive ultrasound/CT, usually persistent drainage (&gt;3 weeks), yes/no signs of infection, yes/no readmission, no sepsis, no reoperation, no death related to fistula
Grade C: &gt;3x normal serum amylase, ill appearing/bad, requires specific treatment, positive ultrasound/CT, persistent drainage (&gt;3 weeks), signs of infection, yes/no readmission, sepsis, reoperation, and death related to fistula</description>
          <population>(1) participant in the mesh reinforcement arm was not evaluable due to death and (1) participant in the non-mesh reinforcement arm was not evaluable due to death.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Any Fistula as Defined by the ISGPF Pancreatic Leak Grading System</title>
        <time_frame>100 days or removal of drain</time_frame>
        <population>(1) participant in the mesh reinforcement arm was not evaluable due to death and (1) participant in the non-mesh reinforcement arm was not evaluable due to death.</population>
        <group_list>
          <group group_id="O1">
            <title>Stapled Transection With Mesh Reinforcement</title>
            <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
          </group>
          <group group_id="O2">
            <title>Stapled Transection Without Mesh Reinforcement</title>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Any Fistula as Defined by the ISGPF Pancreatic Leak Grading System</title>
          <population>(1) participant in the mesh reinforcement arm was not evaluable due to death and (1) participant in the non-mesh reinforcement arm was not evaluable due to death.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Drain Removal</title>
        <time_frame>100 days or removal of drain</time_frame>
        <population>(1) participant in the mesh reinforcement arm was not evaluable due to death and (1) participant in the non-mesh reinforcement arm was not evaluable due to death.</population>
        <group_list>
          <group group_id="O1">
            <title>Stapled Transection With Mesh Reinforcement</title>
            <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
          </group>
          <group group_id="O2">
            <title>Stapled Transection Without Mesh Reinforcement</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Drain Removal</title>
          <population>(1) participant in the mesh reinforcement arm was not evaluable due to death and (1) participant in the non-mesh reinforcement arm was not evaluable due to death.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="6" upper_limit="19"/>
                    <measurement group_id="O2" value="17" lower_limit="7" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Non-pancreatic Adverse Events</title>
        <time_frame>100 days or removal of drain</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stapled Transection With Mesh Reinforcement</title>
            <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
          </group>
          <group group_id="O2">
            <title>Stapled Transection Without Mesh Reinforcement</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Non-pancreatic Adverse Events</title>
          <units>non-pancreatic adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Intraoperative Complications Incurred by Participants</title>
        <time_frame>100 days or removal of drain</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Stapled Transection With Mesh Reinforcement</title>
            <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
          </group>
          <group group_id="O2">
            <title>Stapled Transection Without Mesh Reinforcement</title>
          </group>
        </group_list>
        <measure>
          <title>Intraoperative Complications Incurred by Participants</title>
          <units>intraoperative complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Staple misfire splenic artery requiring revision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding at staple line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic artery injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Umbilical tape in staple line requiring revision</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary embolus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Splenic avulsion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deserosalization of stomach</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Stapled Transection With Mesh Reinforcement</title>
          <description>Mesh reinforced staple line (SEAMGUARD® or PERI-STRIPS DRY®)</description>
        </group>
        <group group_id="E2">
          <title>Stapled Transection Without Mesh Reinforcement</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>ISGPF</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fistula (leak)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Clavien-Dindo</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Gastrointestinal anastomosis leak</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Prolonged ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Other intraabdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Postoperative bleeding requiring transfusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Postoperative bleeding requiring reoperation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction to medication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>IV infiltration with skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>New onset diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Acute renal failure (not requiring dialysis)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="46"/>
              </event>
              <event>
                <sub_title>Vascular psedoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="46"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The investigators were unable to identify any complications directly due to the mesh materials. It is possible these complications are very rare and that the study did not include enough participants to potentially identify these potential harms.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William Hawkins, M.D.</name_or_title>
      <organization>Washington University School of Medicine</organization>
      <phone>314-362-7046</phone>
      <email>hawkinsw@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

